Tuesday, October 05, 2021 12:25:07 PM
We should be hearing results very soon!
TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results of the Phase II trial of its lead drug LSALT peptide (Metablok) is ongoing and will be disclosed to the public following third-party, scientific peer review.
After the recruitment of the last patient into the trial in early May, the Company’s Phase II data team reconciled the patient data collected from the seven clinical sites that participated in the trial. The database containing the trial data was then locked at the end of June, which enabled the start of data analysis in late July. All of the Phase II clinical sites in Canada, the U.S. and Turkey have been officially closed.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM